Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
10
06
2020
accepted:
18
02
2021
revised:
26
01
2021
pubmed:
9
4
2021
medline:
15
12
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Patients received 1 year/18 cycles of pertuzumab/placebo with trastuzumab and chemotherapy and completed EORTC QLQ-C30 and BR23 questionnaires until 36 months post-randomisation/disease recurrence. Changes ≥10 points from baseline were considered clinically meaningful. 87-97% of patients completed questionnaires. In the pertuzumab versus placebo arms, mean decrease in physical function scores (baseline → end of taxane) was -10.7 (95% CI -11.4, -10.0) versus -10.6 (-11.4, -9.9), mean decrease in global health status was -11.2 (-12.2, -10.2) versus -10.2 (-11.1, -9.2), and mean increase in diarrhoea scores (baseline → end of taxane) was +22.3 (21.0, 23.6) versus +9.2 (8.2, 10.2). Diarrhoea scores remained elevated versus baseline in the pertuzumab arm throughout HER2-targeted treatment (week 25: +13.2; end of treatment: +12.2). Role functioning was maintained in both arms. Improved invasive disease-free survival achieved by adding pertuzumab to trastuzumab and chemotherapy did not adversely affect the ability to conduct activities of daily living versus trastuzumab and chemotherapy alone. Patient-reported diarrhoea worsened during taxane therapy in both arms, persisting during HER2-targeted treatment in the pertuzumab arm. CLINICALTRIALS.GOV: NCT01358877.
Sections du résumé
BACKGROUND
We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy).
METHODS
Patients received 1 year/18 cycles of pertuzumab/placebo with trastuzumab and chemotherapy and completed EORTC QLQ-C30 and BR23 questionnaires until 36 months post-randomisation/disease recurrence. Changes ≥10 points from baseline were considered clinically meaningful.
RESULTS
87-97% of patients completed questionnaires. In the pertuzumab versus placebo arms, mean decrease in physical function scores (baseline → end of taxane) was -10.7 (95% CI -11.4, -10.0) versus -10.6 (-11.4, -9.9), mean decrease in global health status was -11.2 (-12.2, -10.2) versus -10.2 (-11.1, -9.2), and mean increase in diarrhoea scores (baseline → end of taxane) was +22.3 (21.0, 23.6) versus +9.2 (8.2, 10.2). Diarrhoea scores remained elevated versus baseline in the pertuzumab arm throughout HER2-targeted treatment (week 25: +13.2; end of treatment: +12.2). Role functioning was maintained in both arms.
CONCLUSIONS
Improved invasive disease-free survival achieved by adding pertuzumab to trastuzumab and chemotherapy did not adversely affect the ability to conduct activities of daily living versus trastuzumab and chemotherapy alone. Patient-reported diarrhoea worsened during taxane therapy in both arms, persisting during HER2-targeted treatment in the pertuzumab arm. CLINICALTRIALS.GOV: NCT01358877.
Identifiants
pubmed: 33828257
doi: 10.1038/s41416-021-01323-y
pii: 10.1038/s41416-021-01323-y
pmc: PMC8257679
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
pertuzumab
K16AIQ8CTM
Trastuzumab
P188ANX8CK
Banques de données
ClinicalTrials.gov
['NCT01358877']
Types de publication
Comparative Study
Journal Article
Pragmatic Clinical Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-47Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Roman, L. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
doi: 10.1056/NEJMoa1113216
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
doi: 10.1056/NEJMoa1413513
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L. M., Liu, M. C. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25–32 (2012).
doi: 10.1016/S1470-2045(11)70336-9
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
doi: 10.1016/S0140-6736(13)62422-8
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122–131 (2017).
doi: 10.1056/NEJMoa1703643
Piccart, M., Procter, M., Fumagalli, D. de Azambuja, E., Clark, E., Ewer, M. S. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J. Clin. Oncol. JCO2001204 (2021). https://doi.org/10.1200/JCO.20.01204 . Epub ahead of print.
Roche Registration Ltd. Perjeta® (pertuzumab). Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf (2019).
Genentech Inc. Perjeta™ (pertuzumab). Prescribing Information (USA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125409s123lbl.pdf (2019).
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365–376 (1993).
doi: 10.1093/jnci/85.5.365
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M. et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J. Clin. Oncol. Cancer 14, 2756–2768 (1996).
doi: 10.1200/JCO.1996.14.10.2756
Fayers, P. M. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur. J. Cancer 37, 1331–1334 (2001).
doi: 10.1016/S0959-8049(01)00127-7
Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139–144 (1998).
doi: 10.1200/JCO.1998.16.1.139
Bines, J., Procter, M., Restuccia, E., Viale, G., Zardavas, D., Suter, T. et al. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin. Breast Cancer 20, 174–181.e3 (2020).
Johansson, B., Brandberg, Y., Hellbom, M., Persson, C., Petersson, L. M., Berglund, G. et al. Health-related quality of life and distress in cancer patients: results from a large randomised study. Br. J. Cancer 99, 1975–1983 (2008).
doi: 10.1038/sj.bjc.6604789
Cortés, J., Baselga, J., Im, Y.-H., Im, S.-A., Pivot, X., Ross, G. et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann. Oncol. 24, 2630–2635 (2013).
doi: 10.1093/annonc/mdt274
Dueck, A. C., Hillman, D. W., Kottschade, L. A., Halyard, M. Y., Sloan, J. A., Flickinger, L. M. et al. Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). J. Clin. Oncol. 32(suppl), 647 (2014).
doi: 10.1200/jco.2014.32.15_suppl.647
Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C. H. et al. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann. Oncol. 30, 567–574 (2019).
doi: 10.1093/annonc/mdz016
Barcenas, C. H., Hurvitz, S. A., Di Palma, J. A., Bose, R., Chien, A. J., Iannotti N., Marx G. et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann. Oncol. 31, 1223–1230 (2020).
Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M. & Brown, J. M. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J. Clin. Oncol. 29, 89–96 (2011).
doi: 10.1200/JCO.2010.28.0107